PLUVICTO is the first and only PSMA-targeted radioligand therapy to significantly improve OS in a phase 3 mCRPC trial1,2
PLUVICTO targets PSMA, a biomarker overexpressed in more than 80% of men with prostate cancer1,3,4
PLUVICTO significantly improved OS1,2
Median OS was 15.3 months with PLUVICTO + BSOC vs 11.3 months with BSOC alone (HR=0.62 [95% CI, 0.52-0.74]; P<0.001)1,2
PLUVICTO has an established safety profile1
Most common ARs (≥20%) with PLUVICTO + BSOC were fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation1
ARs, adverse reactions; BSOC, best standard of care; HR, hazard ratio; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.